diffuse large b-cell lymphoma Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
New/Updated Trials

Male only (2)
Any (305)

Phase 1 (84)
Phase 2 (87)
Phase 3 (21)
Phase 4 (3)
Phase 1/2 (57)
Phase 2/3 (5)
Unknown (50)

Interventional (274)
Observational (29)

National Cancer Institute (NCI) (15)
Fred Hutchinson Cancer Research Center (6)
Ruijin Hospital (6)
Celgene (5)
City of Hope Medical Center (5)
M.D. Anderson Cancer Center (5)
Masonic Cancer Center, University of Minnesota (5)
Mayo Clinic (5)
Memorial Sloan Kettering Cancer Center (5)
University of Washington (5)
Genmab (4)
Novartis Pharmaceuticals (4)
The First Affiliated Hospital with Nanjing Medical University (4)
The Lymphoma Academic Research Organisation (4)
David Bond, MD (3)
Fondazione Italiana Linfomi ONLUS (3)
Henan Cancer Hospital (3)
Huiqiang Huang (3)
Icahn School of Medicine at Mount Sinai (3)
Juno Therapeutics, a Subsidiary of Celgene (3)
Second Affiliated Hospital, School of Medicine, Zhejiang University (3)
Stichting Hemato-Oncologie voor Volwassenen Nederland (3)
Sun Yat-sen University (3)
ADC Therapeutics S.A. (2)
Austin Health (2)
Barbara Ann Karmanos Cancer Institute (2)
BeiGene (2)
Calibr, a division of Scripps Research (2)
Dana-Farber Cancer Institute (2)
Fudan University (2)
Gilead Sciences (2)
H. Lee Moffitt Cancer Center and Research Institute (2)
Herlev Hospital (2)
Hospices Civils de Lyon (2)
Institute of Hematology & Blood Diseases Hospital (2)
Lars Møller Pedersen (2)
MEI Pharma, Inc. (2)
Miltenyi Biomedicine GmbH (2)
Nordic Lymphoma Group (2)
Samsung Medical Center (2)
Seagen Inc. (2)
Shanghai Ming Ju Biotechnology Co., Ltd. (2)
TG Therapeutics, Inc. (2)
Takeda (2)
UNC Lineberger Comprehensive Cancer Center (2)
University Hospital Muenster (2)
University of Chicago (2)
Wuhan University (2)
AIDS Malignancy Consortium (1)
AVM Biotechnology LLC (1)
Academic and Community Cancer Research United (1)
Acerta Pharma BV (1)
Adicet Bio, Inc (1)
Antengene Corporation (1)
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.) (1)
Arcus Biosciences, Inc. (1)
Asan Medical Center (1)
Assistance Publique - Hôpitaux de Paris (1)
AstraZeneca (1)
Autolus Limited (1)
Bambino Gesù Hospital and Research Institute (1)
Baylor College of Medicine (1)
Beijing Boren Hospital (1)
Beijing InnoCare Pharma Tech Co., Ltd. (1)
Beth Christian (1)
Bio-Path Holdings, Inc. (1)
Bnai Zion Medical Center (1)
Boryung Pharmaceutical Co., Ltd (1)
C. Babis Andreadis (1)
Cambridge University Hospitals NHS Foundation Trust (1)
Catherine Bollard (1)
Celldex Therapeutics (1)
Cellectar Biosciences, Inc. (1)
Central Hospital, Nancy, France (1)
Centre Antoine Lacassagne (1)
Centre Hospitalier Universitaire, Amiens (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
Chipscreen Biosciences, Ltd. (1)
Chongqing Precision Biotech Co., Ltd (1)
Constellation Pharmaceuticals (1)
Crystal Mackall, MD (1)
Curis, Inc. (1)
Curocell Inc. (1)
Cyteir Therapeutics, Inc. (1)
CytomX Therapeutics (1)
Deepa Jagadeesh (1)
Dong-A University Hospital (1)
Duke University (1)
Eden BioCell Ltd. (1)
Eli Lilly and Company (1)
Emory University (1)
Epizyme, Inc. (1)
First Affiliated Hospital of Harbin Medical University (1)
First Affiliated Hospital of Zhejiang University (1)
Fox Chase Cancer Center (1)
French Innovative Leukemia Organisation (1)
Fujian Medical University (1)
Fundacion CRIS de Investigación para Vencer el Cáncer (1)
Fundación Academia Española de Dermatología (1)
GWT-TUD GmbH (1)

No (302)
Yes (5)

Updated trials (45)
New trials (4)

I am/have/had

I am/have/hadb-cell lymphoma

I am/have/hadmeasurable disease

I am/have/hadfollicular lymphoma

I am/have/hadhodgkin's disease

I am/have/hadcancer

I am/have/hadgilbert's syndrome

I am/have/hadcell transplantation

I am/have/hadmantle cell lymphoma

I am/have/hadneutrophil count

I am/have/hadhigh grade b-cell lymphoma

I am/have/hadchronic lymphocytic leukemia

I am/have/hadda-epoch

I am/have/hadsalvage therapy

I am/have/hadautograft

I am/have/hadindolent lymphoma

I am/have/hadmarginal zone lymphoma

I am/have/hadburkitt's lymphoma

I am/have/hadchemoimmunotherapy

I am/have/hadleukemia

I am/have/hadline of therapy

added new label for I am/have/had

I am looking for

I am looking forrituximab

I am looking forvincristine

I am looking forcyclophosphamide

I am looking fordoxorubicin

I am looking forprednisone

I am looking foranthracyclines

I am looking foretoposide

I am looking forvenetoclax

I am looking forbendamustine

I am looking forlenalidomide

I am looking foralkylating agent

I am looking formonoclonal antibodies

I am looking foranti-cd20 monoclonal antibody

I am looking forcytarabine

I am looking forconjugated bilirubin

I am looking forbtk inhibitor

I am looking forgemcitabine

I am looking forbrentuximab

I am looking fordexamethasone

I am looking foravid

added new label for I am looking for

Advanced Filters

Found 307 clinical trials

featured

TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US

(diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central nervous system

2163 views
30 Aug, 2021
16 locations

featured

TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish

300 views
26 Mar, 2021
16 locations

featured

Phase 1
For Seniors
For adults
For all genders
Hematology
Recruiting

A safety and Tolerability Study of INCB053915 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety and tolerability of INCB053914 in combination with INCB050465 in relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).

b-cell lymphoma

lymphoma

lymphomas

45 views
25 Aug, 2021
3 locations

featured

For pediatric ages
For adults
For all genders
Recruiting

A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

180 views
25 Mar, 2021
1 location

Multi-country trial
Phase 2
For adults
Recruiting in 100s
Interventional Study
For all genders
Recruiting

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

large B-cell lymphoma (DLBCL).

follicular lymphoma

large cell lymphoma

transformed lymphoma

burkitt's lymphoma

chemoimmunotherapy

32 views
23 Jan, 2021
18 locations

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
For all genders
Recruiting

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participant ramp-up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.

0 views
17 Sep, 2021
33 locations

Phase 3
For adults
Recruiting in 100s
Interventional Study
For all genders
Recruiting

Thalidomide Maintenance Treatment in DLBCL

This is a randomized, multi-center,phase III study to evaluate the ability of thalidomide maintenance therapy to prolong relapse-free survival in diffuse large B cell lymphoma(DLBCL).

rituximab

b-cell lymphoma

15 views
21 Jan, 2021
1 location

Phase 2
For adults
Recruiting in 10s
Interventional Study
For all genders
Recruiting

GVD R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

rituximab) regimen for autologous hematopoietic stem cell transplantation(ASCT)-eligible patients with refractory/relapsed diffuse large B-cell lymphoma.

rituximab

cell transplantation

doxorubicin

b-cell lymphoma

gemcitabine